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Background {#Sec2}
==========

On April 9th 2019, the World Health Organization (WHO) launched a global consultation for the 2021--2030 roadmap on neglected tropical diseases \[[@CR1]\]. An important item on this new roadmap is the elimination of onchocerciasis in most endemic countries. Thanks to the efforts of the Onchocerciasis Control Programme in West Africa (OCP) and the African Programme for Onchocerciasis Control (APOC), during the last 30--40 years great progress has been made towards elimination of onchocerciasis as a public health problem in many African foci \[[@CR2]\]. However to reach the elimination of transmission in all African countries will entail enormous challenges, as has been highlighted by the active discussion around onchocerciasis intervention strategies and evaluation procedures in this journal \[[@CR3]--[@CR6]\].

Main text {#Sec3}
=========

Dadzie et al. in an opinion paper put the question: "Is onchocerciasis elimination in Africa feasible by 2025" in perspective, based on lessons learnt from both OCP and APOC \[[@CR3]\]. They recognise the success of the Onchocerciasis Elimination Program for the Americas in eliminating onchocerciasis transmission in 4 of 6 endemic countries in South America, but consider that the adoption of serology-based criteria for elimination, as used in South America, has unnecessarily prolonged interventions in many areas where APOC's own entomological and parasitological criteria for elimination \[[@CR2]\] were possibly met already.

In response, Cupp et al. \[[@CR4]\] and Richards et al. \[[@CR5]\] maintain that the American experience in the fight against onchocerciasis provides a wealth of research and technical know-how that have already, and would continue to benefit the African continent. They highlight the strategies of twice or more rounds of mass drug administration (MDA) of ivermectin per year, as well as the use of OV16 serology as a decision tool to stop MDA.

These authors disagree about the appropriateness of serology-based criteria for evaluating onchocerciasis elimination in Africa. Indeed, the comparative validity of parasitological versus serological criteria for stopping MDA is unknown. WHO stepped away from using skin snip-based parasitological criteria, in view of its reduced sensitivity at low parasite levels and its invasiveness. Yet, the evidence underlying the more recent serological criteria is still rather weak and optimal ELISA protocols still need to be defined \[[@CR7]\]. The WHO Onchocerciasis Technical Advisory Subgroup (OTS) is in fact working on the evidence base in order to identify strategies to help country elimination committees make valid decisions. Evidence-based serological thresholds, adapted for the African continent, would need to be established. Monitoring for resurgence of onchocerciasis transmission will equally be required. The development of a more sensitive antibody test by integrating multiple biomarkers *of Onchocerca volvulus* infection may lead to a reduction in the number of children to test when assessing elimination thresholds \[[@CR8]\].

The contributors to the current discussion all agree that intensified efforts are needed to achieve the ambitious elimination goal, at least in some areas. APOC had aimed to achieve elimination in 80% of African countries by 2025 \[[@CR9]\], but today it is unlikely that this target will be reached with the current onchocerciasis elimination strategies and available funding. Onchocerciasis-endemic countries in both Africa and South America show considerable variation in the characteristics of the disease and transmission dynamics. Therefore interventions need to be tailored to each onchocerciasis focus.

In hyper-endemic areas with high onchocerciasis-associated morbidity like onchocerciasis-associated epilepsy (OAE), aggressive strategies such as 6-monthly MDA with high coverage and complementary vector control should be deployed, as was the case in northern Uganda \[[@CR10]\]. Such interventions are often considered too expensive, but may turn out to be cost-effective by decreasing morbidity and mortality. Moreover, onchocerciasis morbidity is often the driving factor that will increase community participation and therefore coverage and ultimate success. In hypo-endemic areas, annual community-directed treatment with ivermectin (CDTI) may suffice to stop transmission within 6--8 years, but emphasis must be laid on achieving ≥85% coverage of eligible population. The need for tailored interventions underscores the need for more information, for wider thinking and continuing investigation into the various components of this disease complex (e.g. new assessment tests, better understanding of the clinical disease, reassessing the chemotherapeutic regimes, understanding the clinical and transmission significance of hypo-endemic areas).

In this debate about onchocerciasis elimination, the elimination of onchocerciasis-related morbidity should not be forgotten. It has been suggested that onchocerciasis is not a public health problem anymore \[[@CR1], [@CR3]\]. This is evident for many regions, but is definitely not true throughout Africa \[[@CR11]\]. Recent studies highlighted OAE as a major unrecognised public health problem in many remote onchocerciasis foci where there is inadequate ivermectin coverage such as in parts of the Democratic Republic of Congo \[[@CR12]\], Cameroon \[[@CR13]\], Tanzania \[[@CR14]\] and South Sudan \[[@CR15]\]. This also applies to onchodermatitis, which still exists in many endemic locations. Assessments of the clinical disease are rarely done in national onchocerciasis programs \[[@CR16]\]. Onchocerciasis elimination programs in Africa should take into account OAE and the other clinical presentations of this infection in their elimination and surveillance strategies, and a morbidity management and disease prevention (MMDP) strategy similar to that for lymphatic filariasis will need to be developed \[[@CR17], [@CR18]\]. This will require collaboration between the onchocerciasis elimination program with other partners including primary health and mental health programs**.**

Conclusions {#Sec4}
===========

In developing the roadmap towards onchocerciasis elimination, decision-makers should strive to implement the most effective strategies (bi-annual CDTI, vector control, etc.) albeit their relatively higher costs. As was so successfully done for human immunodeficiency virus infection, the person living with the infection should be the focus of our efforts, not the parasite and not the available budget. It is important to involve the affected communities and advocate for tailored, evidence-based interventions. Finally, we should keep the 2025 target for stopping treatment, but clearly a paradigm shift will be needed.
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APOC

:   African Programme for Onchocerciasis Control

CDTI

:   Community-directed treatment with ivermectin

MDA

:   Mass drug administration

OAE

:   Onchocerciasis-associated epilepsy

OCP

:   Onchocerciasis Control Programme in West Africa

WHO

:   World Health Organization
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